Designing a Fusion Protein Vaccine Against HCV: An In Silico Approach

Atapour, Amir; Mokarram, Pooneh; Mostafavi‐Pour, Zohreh; Hosseini, Seyed Younes; Ghasemi, Younes; Mohammadi, Shiva; Nezafat, Navid

doi:10.1007/s10989-018-9735-4

Cited by 29 publications

(22 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent advancements in computational biology have opened up new doors for designing effective vaccines in silico. [19][20][21]. In this study, the in silico approach has been applied for attaining a multi-epitope vaccine against SARS-CoV-2 that comprises epitopes of spike glycoprotein epitopes which induces the activation of cytotoxic T lymphocytes (CTLs), helper T lymphocytes (HTLs) and interferon-γ (IFN-γ) ( Fig.…”

Section: Introductionmentioning

confidence: 99%

A Candidate multi-epitope vaccine against SARS-CoV-2

Narsaria

Basak

et al. 2020

Preprint

View full text Add to dashboard Cite

In the past two decades, 7 coronaviruses have infected the human population, with two major outbreaks caused by SARS-CoV and MERS-CoV in the year 2002 and 2012, respectively. Currently, the entire world is facing a pandemic of another coronavirus, SARS-CoV-2, with a high fatality rate. The spike glycoprotein of SARS-CoV-2 mediates entry of virus into the host cell and is one of the most important antigenic determinants, making it a potential candidate for a vaccine. In this study, we have computationally designed a multi-epitope vaccine using spike glycoprotein of SARS-CoV-2. The overall quality of the candidate vaccine was validated in silico and Molecular Dynamics Simulation confirmed the stabilityof the designed vaccine. Docking studies revealed stable interactions of the vaccine with Toll Like Receptors and MHC Receptors. Codon optimization was used to optimize high expression of the vaccine in E.coli K-12 strain. In silico cloning suggested efficient expression in pET-28a (+) vector. The efficiency of the candidate vaccine to trigger an effective immune response was assessed by an in silico immune simulation. The computational analyses suggest that the designed multi-epitope vaccine is structurally stable which can induce specific immune responses and thus, can be a potential vaccine candidate against SARS-CoV-2.Authors Tamalika Kar, Utkarsh Narsaria, Srijita Basak, and Debashrito Deb contributed equally to this work.

show abstract

Section: Introductionmentioning

confidence: 99%

A Candidate multi-epitope vaccine against SARS-CoV-2

Narsaria

Basak

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Several research groups have recently applied similar strategy to design a multiepitope vaccine against Klebsiella pneumoniae [88], Kaposi Sarcoma [20], Pseudomonas aeruaginosa [103], Epstein Barr virus [104], Malaria [105], Hendra virus [106] and Nipah virus [107]. Similar approaches have also been used for developing vaccine against cancer antigens [22,[108][109][110] The proposed mechanism of action was also predicted for the nal vaccine model (Fig. 13).…”

Section: Figure13mentioning

confidence: 92%

“…This limitation can be overcome by peptide-based vaccines comprising short immunogenic peptide fragments that can elicit highly targeted immune responses, avoiding the chances of allergenic reactions [20]. Recent advancements in computational biology are very effective in designing various approaches for vaccine synthesis [21][22][23][24]. One of these advancements is the emerging role of immunoinformatics tools in effective vaccine designing [25][26][27][28].…”

Section: Introductionmentioning

confidence: 99%

A Candidate Multi-Epitope Vaccine Against Pathogenic Chandipura Vesiculovirus Identified using Immunoinformatics.

Deb

Basak

Kar

et al. 2020

Preprint

View full text Add to dashboard Cite

Chandipura vesiculovirus (CHPV) is a rapidly emerging pathogen responsible for causing acute encephalitis. Due to its widespread occurrence in Asian and African countries, this has become a global threat, and there is an urgent need to design an effective and non-allergenic vaccine against this pathogen. The conventional method of vaccine design involves large proteins or whole organism which leads to unnecessary antigenic load with increased chances of allergenic reactions. In addition, the process is also very time consuming and labour intensive. These limitations can be overcome by peptide-based vaccines comprising of short immunogenic peptide fragments that can elicit highly targeted immune responses, avoiding the chances of allergenic reactions, in a relatively shorter time span. The multi-epitope vaccine constructed using CTL, HTL and IFN-γ epitopes was able to elicit specific immune responses when exposed to the pathogen, in-silico. Not only that, Molecular Docking and Molecular Dynamics Simulation studies confirmed a stable interaction of the vaccine with the immune receptors. Several physicochemical analyses of the designed vaccine candidate confirmed it to be highly immunogenic and non-allergic. The computer-aided analysis performed in this study suggests that the designed multi-epitope vaccine can elicit specific immune responses and can be a potential candidate against CHPV.

show abstract

“…In this step, peptide-protein docking was performed to predict the binding of epitopes with various antibodies or the MHC receptors [122]. The molecular docking study of the epitopes were as the best docking score [113]- [126]. The best results were visualized using Discovery Studio…”

Section: Molecular Docking Of the Selected Epitopesmentioning

confidence: 99%

The Essential Facts of Wuhan Novel Coronavirus Outbreak in China and Epitope-based Vaccine Designing against COVID-19

Sarkar

Ullah

Johora

et al. 2020

Preprint

View full text Add to dashboard Cite

Wuhan Novel Coronavirus (2019-nCoV) outbreak has become global pandemic which has raised the concern of scientific community to deign and discover a definitive cure against this deadly virus which has caused deaths of numerous infected people upon infection and spreading. To date, there is no antiviral therapy or vaccine is available which can effectively combat the infection caused by this virus. This study was conducted to design possible epitope-based subunit vaccines against the 2019-nCoV using the approaches of reverse vaccinology and immunoinformatics. Upon continual computational experimentation three possible vaccine constructs were designed and one vaccine construct was selected as the best vaccine based on molecular docking study which is supposed to effectively act against the Wuhan Novel Coronavirus. Later, molecular dynamics simulation and in silico codon adaptation experiments were carried out in order to check biological stability and find effective mass production strategy of the selected vaccine. Hopefully, this study will contribute to uphold the present efforts of the researches to secure a definitive treatment against this nasty virus.

show abstract

Designing a Fusion Protein Vaccine Against HCV: An In Silico Approach

Cited by 29 publications

References 66 publications

A Candidate multi-epitope vaccine against SARS-CoV-2

A Candidate multi-epitope vaccine against SARS-CoV-2

A Candidate Multi-Epitope Vaccine Against Pathogenic Chandipura Vesiculovirus Identified using Immunoinformatics.

The Essential Facts of Wuhan Novel Coronavirus Outbreak in China and Epitope-based Vaccine Designing against COVID-19

Contact Info

Product

Resources

About